TrialCancer medicine2019

Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.

Feng-Cai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.